Mild Cognitive Impairment clinical trials at UCSF

11 in progress, 10 open to eligible people

Showing trials for

  • In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Rural Homes

    open to eligible people ages 18 years and up

    This study aims to develop, evaluate, and commercialize an in-home supportive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease, other dementias, or mild cognitive impairment in rural homes.

    Berkeley, California

  • In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Spanish Language Homes

    open to eligible people ages 18 years and up

    This study aims to develop, evaluate, and commercialize an in-home supportive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease, other dementias, or mild cognitive impairment in Spanish language homes.

    Berkeley, California

  • In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Wearables

    open to eligible people ages 18 years and up

    This study aims to develop, evaluate, and commercialize an in-home supportive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease, other dementias, or mild cognitive impairment by integrating wearable devices (e.g., Apple Watches).

    Berkeley, California

  • Multi-domain Online Therapeutic Investigation Of Neurocognition (MOTION)

    open to eligible people ages 55 years and up

    The purpose of this study is to compare the effects of three on-line wellness interventions for improving physical and cognitive function and brain connectivity in adults who are at least 55 years old and are experiencing symptoms of memory and/or cognitive difficulties.

    San Francisco, California

  • Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons

    open to eligible people ages 40 years and up

    The aim of this study is to test whether tesamorelin, in combination with a text-messaging application to help with motivation and adherence, will significantly improve memory and thinking in HIV.

    San Francisco, California and other locations

  • Wayfinding Intervention and Long-Term Memory

    open to eligible people ages 60-85

    Therapeutic treatment is yet available for declining memory, which is an impairment affecting the quality of life for many older adults and patients with cognitive impairment. Cognitive training with an immersive video game promises to drive hippocampal-cortical plasticity and associated gains that can restore memory capability or provide therapeutic treatment for memory deficits.

    San Francisco, California

  • Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol

    open to eligible people ages 55-90

    Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.

    San Francisco, California and other locations

  • Living Alone in Old Age With Cognitive Impairment

    open to eligible people ages 55 years and up

    The purpose of this study is to better understand the experience of living alone in older age with cognitive impairment. We recruit adults 55+ living alone with cognitive impairment such as Alzheimer's disease or mild cognitive impairment. This study investigates the priorities and concerns of older adults living alone with cognitive impairment. Participants are interviewed 5 times for one hour in their homes within 3 months at a time that works for them.

    San Francisco, California

  • Longitudinal Early-onset Alzheimer's Disease Study Protocol

    open to eligible people ages 40-64

    The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EOnonAD) participants, and (3) cognitively normal (CN) control participants.

    San Francisco, California and other locations

  • Remote Cognitive Assessment for Surgical Patients

    open to eligible people ages 65-99

    This is a pilot study to evaluate the use of remote cognitive testing to identify patients who may have cognitive vulnerability and may benefit from cognitive care pathways. Participants in this study are asked to complete a smartphone battery of thinking, memory, speech, and motor function tests on their smartphone.

    San Francisco, California

  • The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia

    Sorry, in progress, not accepting new patients

    Older adults at risk for dementia show a variety of cognitive deficits, which can be ameliorated by different cognitive training (CT) exercises. The best combination of CT exercises is unknown. The aim is to discover the most efficacious combination of CT exercises as compared to cognitive stimulation (which will serve as a stringent, active control) to modify the functional trajectories of older adults' with MCI, who are at high risk for dementia. The primary objective of the U01 phase is to design and pilot-test an adaptive, randomized clinical trial (RCT) of cognitive training (CT) combinations aimed to enhance performance of instrumental activities of daily living (IADL) among persons with mild cognitive impairment (MCI). The longitudinal endpoint goal is reducing incident dementia. The primary aim of the study is to determine which CT combination has the best probability to delay dementia by producing the largest IADL improvements. The study further aims to explore neuroimaging and novel blood-based biomarkers.

    San Francisco, California and other locations

Our lead scientists for Mild Cognitive Impairment research studies include .

Last updated: